Eurofins acquires biopharmaceutical company Alphora Research, Inc.
Eurofins Scientific announces the acquisition of Alphora Research Inc., a full service contract research, development and manufacturing organization (CRDMO) for complex and niche small molecule active pharmaceutical ingredients (APIs), based in Mississauga, Ontario, Canada.
Alphora has extensive capabilities in multi-step syntheses, as well as the development of cytotoxic and highly potent APIs. It operates two fully integrated facilities to address a wide array of API challenges, providing a full spectrum of complex API development, testing and manufacturing services. As such the company supports biopharmaceutical companies from the preclinical phase through to commercialization of niche products, and is an ideal complement to Eurofins’ discovery and other biopharmaceutical testing activities. Alphora has grown rapidly since it was founded in 2003, and expects to generate revenues in excess of CAD 30m in 2017, with organic growth and EBITDA margin well above Eurofins’ objectives.
Alphora’s expertise in API development, testing and manufacturing provides Eurofins entry into the dynamic and growing CRDMO market. It is uniquely positioned to capitalize on the strong growth and positive trends in the API industry, which are driven by the increasing importance of outsourcing in biopharmaceutical R&D, limited API manufacturing capacity in North America, and increased funding for early stage discovery and development. Furthermore, Alphora is ideally positioned to support the development of discovery candidates that emerge from Eurofins’ extensive drug discovery platform. In addition to Eurofins’ existing capabilities in preclinical, clinical, and GMP product testing, this acquisition of Alphora further strengthens the Group’s highly compelling and integrated offering to enable clients to progress through the entire drug development process.
Comment from Dr. Gilles Martin, Eurofins CEO: “We are pleased to welcome Alphora to the Eurofins Group. Alphora’s competencies and footprint further strengthen Eurofins’ global leadership in the rapidly-growing biopharmaceutical testing market. We look forward to strengthening their portfolio and operating footprint by providing access to the full range of services and capabilities of the Group.”
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Materials Research Says Yes to Wood - Green alternatives to fossil raw materials: Bio-based materials are expected to reduce pollution and drive the shift to a more sustainable economy
Parasitology: Mother cells as organelle donors
Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration to Discover New CF Drugs - New effort will search for potential therapies targeting the most common mutation of cystic fibrosis
Global Pharmaceutical companies expect hard price competition in the rising Biosimilars segment - Bi-annual survey among more than 80 executives from globally active pharmaceutical companies based in 16 countries and spread over four continents
